FierceBiotech 2026年3月4日 Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset
FierceBiotech 2026年3月3日 New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program
FierceBiotech 2026年3月3日 Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
FierceBiotech 2026年3月3日 MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit
FierceBiotech 2026年3月3日 Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug
FierceBiotech 2026年3月3日 GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels
FierceBiotech 2026年3月3日 HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic
FierceBiotech 2026年3月2日 Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
FierceBiotech 2026年3月2日 TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio
FierceBiotech 2026年3月2日 Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline
FierceBiotech 2026年3月2日 United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition
FierceBiotech 2026年3月2日 UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
FierceBiotech 2026年3月2日 Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock